公开(公告)号：US20240360223A1

公开(公告)日：2024-10-31

申请号：US18622766

申请日：2024-03-29

Applicant: Dragonfly Therapeutics, Inc.

Inventor： Aaron BELLI ,  Ann F. CHEUNG ,  Stacey V. DRABIC ,  Daniel FALLON ,  Benjamin FISCHER ,  Asya GRINBERG ,  Pyae P. HEIN ,  Alexander IVANOV ,  Zong Sean JUO ,  Mark LEWANDOWSKI ,  Xinbi LI ,  Matthew SCHNEIDER

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2851 ,  C07K16/283 ,  C07K16/2878 ,  A61K39/00 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76

Abstract: Multispecific binding proteins that bind NKG2D receptor, CD16, and B cell-activating factor receptor (BAFF-R) are described, as well as pharmaceutical compositions and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer and autoimmune inflammatory diseases.

公开(公告)号：US20240352131A1

公开(公告)日：2024-10-24

申请号：US18637068

申请日：2024-04-16

Applicant: TrueBinding, Inc.

Inventor： Dongxu Sun ,  Suhail Rasool ,  Barbara Rangel da Silva

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P27/02 ,  A61P27/12

CPC classification number: C07K16/2851 ,  A61K9/0048 ,  A61P27/02 ,  A61P27/12 ,  A61K2039/505 ,  C07K2317/565

Abstract: Provided herein are anti-Gal3 antibodies and methods of use thereof. Such methods include therapies for treating one or more eye diseases including, but not limited to, dry eye disease, glaucoma, age-related macular degeneration, microvascular dysfunction, cataracts, retinal drusen, tear dysfunction, corneal sensitivity, diabetic retinopathy, ocular surface diseases, and other eye diseases.

公开(公告)号：US20240279346A1

公开(公告)日：2024-08-22

申请号：US18582950

申请日：2024-02-21

Applicant: Immunitas Therapeutics, Inc.

Inventor： Alison TISDALE ,  Uli BIALUCHA ,  George PUNKOSDY ,  Alexandria FUSCO ,  Frano IRVINE ,  Emily ROSENTRATER ,  Elizabeth SCANLON ,  Michael BATTLES

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  G01N33/68

CPC classification number: C07K16/2851 ,  A61P35/00 ,  A61P37/04 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  G01N2333/70596 ,  G01N2800/52

Abstract: The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers. In addition, the invention also relates to expression vectors and host cells for making these antibodies

公开(公告)号：US20240270861A1

公开(公告)日：2024-08-15

申请号：US18620824

申请日：2024-03-28

Applicant: Dragonfly Therapeutics, Inc.

Inventor： Aaron BELLI ,  Ann F. CHEUNG ,  Stacey V. DRABIC ,  Daniel FALLON ,  Benjamin FISCHER ,  Asya GRINBERG ,  Pyae P. HEIN ,  Alexander IVANOV ,  Zong Sean JUO ,  Mark LEWANDOWSKI ,  Xinbi LI ,  Matthew SCHNEIDER

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/283 ,  C07K16/2851 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/21

Abstract: Multispecific binding proteins that bind NKG2D receptor, CD16, and B cell-activating factor receptor (BAFF-R) are described, as well as pharmaceutical compositions and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer and autoimmune inflammatory diseases.

公开(公告)号：US20240262930A1

公开(公告)日：2024-08-08

申请号：US18561413

申请日：2022-05-27

Applicant: XYONE THERAPEUTICS INC. ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： Surender KHARBANDA ,  Govindaswamy PANCHAMOORTHY ,  Donald W. KUFE

IPC: C07K16/30 ,  A61K45/06 ,  A61K47/68 ,  A61K47/69 ,  A61P35/02 ,  C07K16/28 ,  C07K16/32

CPC classification number: C07K16/3092 ,  A61K45/06 ,  A61K47/6849 ,  A61K47/6889 ,  A61K47/6913 ,  A61P35/02 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/283 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734

Abstract: The present disclosure is directed to multispecific antibody constructs binding to MUC1-C/extracellular domain (MUC1-C/ECD) and to at least’ one other binding target, wherein the binding target comprising CD3 (cluster of differentiation 3). Also provided are methods of using such constructs to treat cancers that express the MUC1 antigen. Further disclosed are sequences of recombinant multispecific antibodies.

公开(公告)号：US20240262912A1

公开(公告)日：2024-08-08

申请号：US18528535

申请日：2023-12-04

Applicant: Merus N.V.

Inventor： Alexander Berthold Hendrik BAKKER ,  Cornelis Jacob Johannes George BOL ,  Pieter Fokko VAN LOO ,  Leonardo Andres SIRULNIK ,  Ernesto Isaac WASSERMAN

IPC: C07K16/28 ,  A61K35/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2809 ,  A61K35/28 ,  A61P35/00 ,  C07K16/2851 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/92

Abstract: The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.

公开(公告)号：US20240247068A1

公开(公告)日：2024-07-25

申请号：US18030584

申请日：2021-10-05

Applicant: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY

Inventor： Yeongjin HONG ,  Jung-Joon MIN ,  Sung-Hwan YOU ,  Ramar THANGAM

IPC: C07K16/28 ,  A61K47/68 ,  A61K49/00 ,  A61K49/16 ,  A61K51/10 ,  A61P35/00 ,  C07K14/47

CPC classification number: C07K16/2851 ,  A61K47/6803 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/6805 ,  A61K47/6809 ,  A61K47/6815 ,  A61K47/6843 ,  A61K49/0045 ,  A61K49/0047 ,  A61K49/0058 ,  A61K49/16 ,  A61K51/1018 ,  A61P35/00 ,  C07K14/47 ,  C07K2317/569 ,  C07K2319/30

Abstract: The present invention provides a novel protein specifically binding to calreticulin and having the scaffold of human fibronectin domain III and a use thereof, wherein the protein can be used for diagnosing cell damage in an early stage to early determine cancer therapy effects and rapidly evaluate in vivo toxicity, thus finding advantageous applications as a candidate material for probes for in vivo diagnosis and treatment of cancer.

公开(公告)号：US20240166753A1

公开(公告)日：2024-05-23

申请号：US18482629

申请日：2023-10-06

Applicant: Dragonfly Therapeutics, Inc.

Inventor： Gregory P. Chang ,  Ann F. Cheung ,  William Haney ,  Asya Grinberg

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/32 ,  C07K16/46

CPC classification number: C07K16/2851 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/283 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/569 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/94

Abstract: Multi-specific binding proteins that bind a tumor associated antigen, the NKG2D receptor, and CD16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

公开(公告)号：US20240150471A1

公开(公告)日：2024-05-09

申请号：US18502668

申请日：2023-11-06

Applicant: Xencor, Inc.

Inventor： Matthew S. Faber

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC classification number: C07K16/2851 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/732

Abstract: Described herein are antibodies, including multispecific antibodies, that bind to NK cells, optionally a tumor target antigen (TTA) and have increased binding to the CD16A receptor. The antibodies can include an NK cell antigen binding domain (ABD) that binds to the extracellular domain of an NK cell antigen such as NKG2D, NKp30, and NKp46.

公开(公告)号：US11958891B2

公开(公告)日：2024-04-16

申请号：US16481001

申请日：2018-01-26

Applicant: Surrozen Operating, Inc.

Inventor： Zhengjian Zhang ,  Jennifer Jean Brady ,  Aaron Ken Sato ,  Wen-Chen Yeh ,  Yang Li ,  Teppei Yamaguchi

IPC: C07K14/705 ,  A61K47/65 ,  C07K14/47 ,  C07K16/28 ,  C07K16/40 ,  C07K19/00 ,  C12N15/62

CPC classification number: C07K14/705 ,  A61K47/65 ,  C07K14/47 ,  C07K16/2851 ,  C07K16/2881 ,  C07K16/40 ,  C12N15/62 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/75 ,  C07K2319/30

Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.